Intelligence Platform

Patents

Browse 837 pharma-relevant patents (US and EP, A61K/A61P) linked to tracked companies. Patent cliff and LOE intelligence for BD teams.

29,054 patents indexed

patent

US 11576984

Genetically modified mouse with humanized immunoglobulin heavy chain constant region genes

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 14 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 09 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11571636

Methods for quantitating individual antibodies from a mixture

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11571482

Human antibodies to S. aureus Hemolysin A toxin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Feb 07 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 02 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559576

Anti-human papillomavirus (HPV) antigen-binding proteins and methods of use thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559564

Use of a VEGF antagonist to treat angiogenic eye disorders

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11559489

Tuning of release kinetics in hydrogels

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 24 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 19 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11547101

Non-human animals having a disruption in a C9ORF72 locus

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548947

Bispecific anti-PSMA X anti-CD28 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11548932

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 10 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 05 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11542317

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11542326

Anti-IL-25 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 03 2023 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11535675

Antigen-binding proteins that antagonize leptin receptor

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11535663

Methods for producing aflibercept in chemically defined media having reduced aflibercept v

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 27 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 22 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11530255

Human antibodies to Ebola virus glycoprotein

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 20 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 15 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11525001

Anti-CD8 antibodies and uses thereof

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11525629

Target residual moisture content for lyophilized drug product

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 13 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 08 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11519020

Methods of associating genetic variants with a clinical outcome in patients suffering from

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11518804

Method of treating osteoarthritis with an antibody to NGF

REGENERON PHARMACEUTICALS, INC. · Granted Tue Dec 06 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 01 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11512309

Treatment of ophthalmic conditions with angiopoietin-like 7 (ANGPTL7) inhibitors

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11511001

Radiolabeled anti-LAG3 antibodies for immuno-PET imaging

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 29 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 24 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505593

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11504390

Treatment of increased lipid levels with sterol regulatory element binding transcription f

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11504426

Methods for treating allergy and enhancing allergen-specific immunotherapy by administerin

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted patent

US 11505594

Anti-VEGF protein compositions and methods for producing the same

REGENERON PHARMACEUTICALS, INC. · Granted Tue Nov 22 2022 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 17 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

granted